High frequency of multidrug-resistant Mycobacterium tuberculosis isolates in Georgetown, Guyana

Authors


Authors
Nikolai Menner, Jutta Wagner, Helmut Hahn, and Ralf Ignatius (corresponding author), Department of Medical Microbiology and Immunology of Infection, Charité– University Medicine Berlin, Benjamin Franklin Campus, Hindenburgdamm 27, 12203 Berlin, Germany. Tel.: +49 30 8445 3620; Fax: +49 30 8445 3830; E-mail: ralf.ignatius@charite.de
Ingo Günther, Faculty of Health Sciences, School of Medicine, University of Guyana, Turkeyen Campus, East Coast Demerara, P.O. Box 101110, Georgetown, Guyana.
Helmut Orawa, Department of Biostatistics and Clinical Epidemiology, Charité– University Medicine Berlin, Benjamin Franklin Campus, Hindenburgdamm 30, 12200 Berlin, Germany.
Andreas Roth, Institute for Microbiology, Immunology, and Laboratory Medicine, Hospital Zehlendorf-Heckeshorn, Zum Heckeshorn 33, 14109 Berlin, Germany
Indal Rambajan and Shamdeo Persaud, Ministry of Health, Guyana, 11 Brickdam Stabroek, Georgetown, Guyana.

Summary

Emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis isolates constitutes a threat to public health worldwide. This study aimed at acquiring first epidemiological data for Guyana. Thirty-six M. tuberculosis isolates from patients of the Georgetown Chest Clinic were subjected to susceptibility testing on solid agar and in broth media. Resistance to at least one first-line drug was observed in 8 (22.2%, 95% confidence interval 8.3–36.1%) and simultaneous resistance to rifampicin and isoniazid (MDR) in 4 (11.1%, 95% confidence interval 0.6–21.6%) of the 36 isolates. The risk of infection with resistant isolates was significantly related to earlier antituberculosis therapy (P = 0.040). These data indicate a high proportion of resistant M. tuberculosis isolates in Guyana and call for the implementation of control strategies based on an improved laboratory diagnosis of TB.

Ancillary